Filing Flows › Pulmonx (LUNG) › Q1 2025
Pulmonx (LUNG) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 2, 2025
Pulmonx (LUNG) reported revenue of $22.5M for the first quarter 2025 (Q1 2025), +20% from a year earlier and -5% from the quarter before. Operating margin was -64.6%, net loss $14.4M (64.1% of revenue).
Pulmonx, Q1 2025: revenue $22.5M (+20% year over year), operating margin -64.6%, net loss $14.4M, operating cash flow −$13.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $22.5M | -5% | +20% |
| Operating profit | −$14.6M | — | — |
| Net earnings | −$14.4M | — | — |
| Operating cash flow | −$13.2M | — | — |
What changed
Revenue was $22.5M in Q1 2025, up 20% year over year and down 5% from the previous quarter.
Gross margin was 72.5%, down 2.2 points from a year earlier. Operating costs exceeded revenue by $14.6M, an operating margin of -64.6%. Operating expenses grew 8% against revenue growth of 20%. The fastest-growing cost line was Research & development (+13%). The quarter ended with a net loss of $14.4M, wider than the previous quarter's $13.2M loss.
Operating cash flow was −$13.2M. Non-cash charges added back $300K of depreciation and $5.6M of share-based compensation. Working capital and other items used $4.7M. Capital expenditures of $301K exceeded it, leaving free cash flow of −$13.5M.
Questions
What was Pulmonx's revenue in the first quarter 2025?
Pulmonx (LUNG) reported revenue of $22.5M for the first quarter 2025 (Q1 2025), +20% from a year earlier and -5% from the quarter before.
Was Pulmonx profitable in the first quarter 2025?
Operating loss was $14.6M (-64.6% of revenue) and net loss $14.4M.
Source: Pulmonx 10-Q on SEC EDGAR.